VST BIO Secures $45 Million Series A Funding
VST BIO, a biotechnology firm based in San Diego, California, has announced the successful closure of a $45 million Series A funding round. The company, which focuses on developing treatments for vascular-related diseases, plans to use the funds to advance its lead stroke therapy candidate, VB-001. The financing was led by Coefficient Giving, a funder known for supporting high-impact scientific and global health projects.
Advancing Stroke Therapy VB-001
VST BIO is concentrating its efforts on VB-001, a monoclonal antibody designed to target vascular inflammation and edema. This therapy holds promise for treating conditions such as acute ischemic stroke, sepsis, and cytokine release syndrome. The company aims to advance VB-001 into first-in-human clinical trials by 2026, marking a significant step in its development pipeline.
Krisztina Zsebo, co-founder and CEO of VST BIO, expressed her optimism about the potential impact of VB-001, stating: "The positive results of our monoclonal antibody in stroke preclinical studies demonstrated the potential of VB-001 to become an important treatment for patients with acute ischemic stroke."
Strategic Use of Funds
The newly acquired funds will not only support the clinical advancement of VB-001 but also help expand VST BIO’s therapeutic platform and enhance its core development capabilities. This expansion is crucial as the company remains at the preclinical stage, focusing on first-in-class antibody therapies for vascular conditions.
Leadership and Expertise
As part of this funding round, VST BIO has appointed William Sessa to its Board of Directors. Sessa brings extensive experience from his previous role as Senior Vice President and Chief Scientific Officer for Internal Medicine at Pfizer. His expertise in translating vascular therapeutics from basic research to clinical trials is expected to be valuable for VST BIO’s future growth.
Michael Simons, co-founder of VST BIO, highlighted the importance of Sessa’s role, saying: "Bill Sessa brings decades of experience in translating vascular therapeutics from basic research to proof-of-concept clinical trials, that will be invaluable as we enter our next phase of growth."
Looking Ahead
With this significant funding boost, VST BIO is well-positioned to advance its innovative therapies and potentially transform the landscape for patients suffering from debilitating vascular diseases. The company’s focus on leveraging cutting-edge research to develop effective treatments underscores its commitment to addressing unmet medical needs in the field of vascular health.